13
views
0
recommends
+1 Recommend
1 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: not found

      The WHO R&D Blueprint: 2018 review of emerging infectious diseases requiring urgent research and development efforts

      review-article

      Read this article at

      ScienceOpenPublisherPMC
      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          The Research and Development (R&D) Blueprint is a World Health Organization initiative to reduce the time between the declaration of a public health emergency and the availability of effective diagnostic tests, vaccines, and treatments that can save lives and avert a public health crisis. The scope of the Blueprint extends to severe emerging diseases for which there are insufficient or no presently existing medical countermeasures or pipelines to produce them. In February 2018, WHO held an informal expert consultation to review and update the list of priority diseases, employing a prioritization methodology which uses the Delphi technique, questionnaires, multi-criteria decision analysis, and expert review to identify relevant diseases. The committee determined that, given their potential to cause a public health emergency and the absence of efficacious drugs and/or vaccines, there is an urgent need for accelerated R&D for (in no order of priority) Crimean-Congo haemorrhagic fever, Ebola virus and Marburg virus disease, Lassa fever, Middle East Respiratory Syndrome (MERS) and Severe Acute Respiratory Syndrome (SARS), Nipah and henipaviral diseases, Rift Valley fever and Zika virus disease. The experts also included “Disease X,” representing the awareness that a previously unknown pathogen could cause a major public health emergency. This report describes the methods and results of the 2018 prioritization review.

          Highlights

          • Emerging infectious diseases pose an important threat for humans.

          • Many of these diseases do not have medical countermeasures.

          • WHO and partners are tackling this issue to advance product R&D for a set of emerging priority diseases.

          • A methodology has been developed and externally reviewed in 2016 to identify a priority list of diseases in need of R&D.

          • This methodology was applied in 2017 and 2018 to review the WHO R&D Blueprint priority list of diseases.

          Related collections

          Most cited references1

          • Record: found
          • Abstract: found
          • Article: not found

          World Health Organization Methodology to Prioritize Emerging Infectious Diseases in Need of Research and Development

          The World Health Organization R&D Blueprint aims to accelerate the availability of medical technologies during epidemics by focusing on a list of prioritized emerging diseases for which medical countermeasures are insufficient or nonexistent. The prioritization process has 3 components: a Delphi process to narrow down a list of potential priority diseases, a multicriteria decision analysis to rank the short list of diseases, and a final Delphi round to arrive at a final list of 10 diseases. A group of international experts applied this process in January 2017, resulting in a list of 10 priority diseases. The robustness of the list was tested by performing a sensitivity analysis. The new process corrected major shortcomings in the pre–R&D Blueprint approach to disease prioritization and increased confidence in the results.
            Bookmark

            Author and article information

            Contributors
            Journal
            Antiviral Res
            Antiviral Res
            Antiviral Research
            Elsevier B.V.
            0166-3542
            1872-9096
            24 September 2018
            November 2018
            24 September 2018
            : 159
            : 63-67
            Affiliations
            [a ]World Health Organization, Switzerland
            [b ]Future of Humanity Institute, University of Oxford, UK
            Author notes
            []Corresponding author. simehandm@ 123456who.int
            [a]

            Massinissa Si Mehand and Farah Al Shorbaji contributed equally to this paper.

            Article
            S0166-3542(18)30564-3
            10.1016/j.antiviral.2018.09.009
            7113760
            30261226
            661c5c81-c308-4e8b-90e6-ea6eda118e4c
            © 2018 Elsevier B.V. All rights reserved.

            Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.

            History
            : 17 September 2018
            : 18 September 2018
            Categories
            Article

            Infectious disease & Microbiology
            severe emerging infectious diseases,prioritization,multi-criteria decision analysis,experts' opinions,multidisciplinary method

            Comments

            Comment on this article